CSL Limited (ASX: CSL) shares are edging lower for a second day in a row.
Though, longer term shareholders arenât likely to be overly bothered. Since this time last year, the biotherapeutics companyâs shares are up over 15%.
This compares favourably to a 1.5% gain by the ASX 200 index over the same period.
Can CSL shares continue to outperform?
The good news is that one leading broker believes that CSLâs shares can continue their outperformance over the remainder of 2023.
In response to the companyâs half years results release earlier this week, the team at Citi has urged investors to pick up shares.
According to the note, the broker has reiterated its buy rating and lifted its price target to $350.
Based on the current CSL share price of $303.61, this implies potential upside of 15% for investors over the next 12 months.
What did the broker say?
Citi was pleased with CSLâs half year results and has upgraded its near term earnings estimates partly to reflect a quicker than expected recovery in plasma collections. It is also now expecting a result ahead of guidance in FY 2023.
And with the broker believing that CSL shares should trade at an FY 2025 price-to-earnings ratio of 28x, it believes fair value is now $350. Citi explained:
We increase our FY23-25e NPATA per share (Core EPS) by +1%/+7%/+10% reflecting the faster than expected recovery in plasma collections and higher sales. Our TP moves to $350 (from $335) Maintain Buy. Our TP implies CSL should trade on an FY25 PE of ~28x, in line with the 10-year average. The key risk to FY24 and FY25 remains the pace of recovery of plasma collections, and Behring gross margins. Our FY23 NPATA of US$2,669m is ~2% above the top-end of guidance.
The post Top broker says CSL shares will hit $350, buy now appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of February 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Top brokers name 3 ASX shares to buy today
- Are CSL shares a buy following the ASX 200 giant’s latest results?
- Everything you need to know about the boosted CSL dividend
- CSL share price lifts on half-year earnings beat
- CSL share price on watch amid US$1.6b profit
Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/94M6nUx
Stock Pick 